索拉非尼在中晚期肝细胞肝癌治疗中的临床价值-东南大学学报医学版

索拉非尼在中晚期肝细胞肝癌治疗中的临床价值

单位：1. 东南大学附属第二医院介入科, 江苏南京 210003;
2. 东南大学附属第二医院放射科, 江苏南京 210003

分类号：R735.7

出版年·卷·期（页码）：2016·35·第一期（106-108）

摘要：

目的:探讨索拉非尼在中晚期肝细胞肝癌联合治疗中的临床价值。方法:回顾性分析21例口服索拉非尼的中晚期肝细胞肝癌患者的临床资料,其中12例患者单纯行经肝动脉化疗栓塞术(TACE)治疗,2例患者行超声聚焦刀和生物治疗,4例患者行TACE结合微波消融治疗,3例患者行TACE、微波消融和生物综合治疗。结果:21例患者中完全缓解(CR)2例(9.5%),部分缓解(PR)3例(14.3%),疾病稳定(SD)10例(47.6%),疾病进展(PD)6例(28.6%),临床获益率(CBR)为71.4%。结论:索拉非尼在中晚期肝细胞肝癌综合治疗中明显提高患者临床获益率,延长肿瘤进展时间。

Objective:To investigate the clinical value of sorafenib in combination treatment for advanced hepatocellular carcinoma. Methods:21 advanced hepatocellular carcinoma patients receiving sorafenib were retrospectively analyzed, in which 12 patients were only treated with transcatheter arterial chemoembolization(TACE), 2 patients were treated with biotherapy and high intensity focused ultrasound, 4 patients were treated with TACE and radio frequency current ablation, 3 patients were treated with TACE, biotherapy and radio frequency current ablation. Results:2 patients achieved a complete response (CR 9.5%), 3 patients achieved a partial response (PR 14.3%), 10 patients had stable disease (SD 47.6%), 6 patients had progressive disease (PD 28.6%), and clinical benefit rate (CBR) was 71.4%. Conclusion:Sorafenib in combination treatment for advanced hepatocellular carcinoma can increase clinical benefit rate and prolong the time to tumor progression.

参考文献：

[1] 陈荔,滕皋军.TACE对原发性肝癌肝功能的损伤[J].东南大学学报:医学版,2012,31(5):643-647.
[2] SHIM J H,PARK J W,CHOI J I,et al.Practical efficacy of sorafenibmonotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area[J].J Cancer Res Clin Ocol,2009,135(10):617-625.
[3] CHENG A,KANG Y,CHEN Z,et al.Efficacy and safety of sorafenib in patients in Asia-Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomized,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
[4] GARNETT M J,MARAIS R.Guilty as charged:B-RAF is ahuman oncogene[J].Cancer Cell,2004,6(4):313-319.
[5] CHANG Y S,ADNANE J,TRAIL P A,et al.Sorafenib inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models[J].Cancer Chemother Pharmacol,2007,59(5):561-574.
[6] LLOVET J M,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
[7] LLOVET J M,BURROUGHS A,BRUIC J.Hepatocellular carcinoma[J].Lancet,2003,362(9399):1907-1917.
[8] CHU D,LACOUTURE M E,FILLOS T,et al.Risk of hand-foot skin reaction with sorafenib:a systematic review and meta-analysis[J].Acta Oncol,2008,47(4):176-186.
[9] 庞旭峰,余晓晨,王祖森,等.肝癌患者服用索拉非尼不良反应的严重性及其与预后的关系[J].山东医药,2013,53(43):80-81.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录